La Mesa-based Regen BioPharma Inc. announced that it added three internationally renowned cancer stem cell experts to its scientific advisory board: Santosh Kesari, Rohit Duggal and Boris Minevis.

Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a professor of Neurosciences at the UC San Diego School of Medicine.

Rohit Duggal has 17 years of professional experience in the drug discovery field, having worked at Pfizer Inc. as a leader of the cancer stem cell group. He has led development of drugs that entered clinical trials, having experience in translating small molecules into clinical candidates, including development of Filibuvir, for which he was granted the Pfizer Achievement Award. At Genelux Corp., he established the cancer stem cell program, which aimed to use viruses to selectively target these cancer initiating cells.

Dr. Boris Minevis director of Immunotherapy and Translational Oncology at Genelux Corp. studying the phenotype and characterization of metastasized cancer stem cells in circulation. Minev previously worked as the principal investigator at the Laboratory of Tumor Immunology and Immunotherapy at the Moores Cancer Center. He has an extensive experience with cancer vaccines, having worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine).